-
Europe
-
Preclinical (R&D)
Completed
-
Feasibility Study
Completed
-
PRIMAvera Study
Ongoing
-
CE Mark
Ongoing
-
Commercial Launch
-
-
United States
-
Preclinical (R&D)
Completed
-
Feasibility Study
Ongoing
-
Clinical Trial
-
Limited Availability
-
General Availability
-
Age-related macular degeneration (AMD) is a degenerative disease that causes a progressive loss of central vision.
The vision loss is concentrated in the macula, the central area of the retina responsible for high-detail vision for tasks like face recognition or reading. AMD is commonly classified into dry AMD caused by a thinning of the retina as photoreceptors degenerate or wet AMD caused by abnormal blood vessels in the retina.
![Illustration of a healthy retina showing light entering and traveling through the first two layers of the retina, getting absorbed by the third, and converted into a visual signal.](/_astro/DiseaseExample1.B3u8I35J_1z2unl.png)
![Illustration of a diseased retina showing light entering and traveling through the first two layers of the retina, and not producing any further signal.](/_astro/DiseaseExample2A.DX2dI2_q_Vkmk1.png)
![Illustration showing the action of the PRIMA implant as it stimulates remaining intact neurons.](/_astro/prima-implant.CurNYOiZ_1HDCpd.png)
Our Approach to Treatment
The PRIMA implant builds on decades of research to miniaturize solar technology. It is inserted into the subretinal space where the photoreceptors have degenerated, and electrical stimulation activates the remaining intact neurons to restore vision.
Learn more about PRIMACurrent Status
Science’s PRIMAvera clinical study is focused on AMD and is ongoing in Europe. This study seeks to evaluate the safety and efficacy of the PRIMA implant on patients with AMD while a separate feasibility study in the US continues.
Resources
More information about treatment options, disease details, and current research